WO2006045314A3 - Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease - Google Patents

Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease Download PDF

Info

Publication number
WO2006045314A3
WO2006045314A3 PCT/DK2005/000689 DK2005000689W WO2006045314A3 WO 2006045314 A3 WO2006045314 A3 WO 2006045314A3 DK 2005000689 W DK2005000689 W DK 2005000689W WO 2006045314 A3 WO2006045314 A3 WO 2006045314A3
Authority
WO
WIPO (PCT)
Prior art keywords
increasing
body mass
lean body
treatment
growth hormone
Prior art date
Application number
PCT/DK2005/000689
Other languages
French (fr)
Other versions
WO2006045314A2 (en
Inventor
Birgitte Holst Lange
Hans T Schambye
Tina Geritz Nielsen
Original Assignee
Gastrotech Pharma As
Birgitte Holst Lange
Hans T Schambye
Tina Geritz Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastrotech Pharma As, Birgitte Holst Lange, Hans T Schambye, Tina Geritz Nielsen filed Critical Gastrotech Pharma As
Publication of WO2006045314A2 publication Critical patent/WO2006045314A2/en
Publication of WO2006045314A3 publication Critical patent/WO2006045314A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)

Abstract

The present invention relates to a method for increasing or maintaining lean body mass in an individual in need thereof, by administering a secretagogue. The present invention also relates in another aspect to the use of a secretagogue for the production of a medicament for use in increasing or maintaining an individual's lean body mass, preferably in an individual suffering from, or at risk of suffering from, cachexia, such as cancer cachexia.
PCT/DK2005/000689 2004-10-27 2005-10-26 Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease WO2006045314A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200401657 2004-10-27
DKPA200401657 2004-10-27
US65311605P 2005-02-16 2005-02-16
US60/653,116 2005-02-16
DKPA200500242 2005-02-16
DKPA200500242 2005-02-16

Publications (2)

Publication Number Publication Date
WO2006045314A2 WO2006045314A2 (en) 2006-05-04
WO2006045314A3 true WO2006045314A3 (en) 2007-04-12

Family

ID=36228137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000689 WO2006045314A2 (en) 2004-10-27 2005-10-26 Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease

Country Status (1)

Country Link
WO (1) WO2006045314A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US7704955B2 (en) 2004-11-24 2010-04-27 Neopro Pain, Inc. Methods and compositions for modulating conditions in both mammals and plants
WO2007112453A2 (en) 2006-03-28 2007-10-04 Neopro Labs, Llc Methods amd compositions for treating conditions
EP2118080B1 (en) 2007-02-09 2016-08-31 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2008144675A1 (en) 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
RU2010114062A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF THE PEPTIDE Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys AS A THERAPEUTIC
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
AU2016229848A1 (en) * 2015-03-09 2017-10-26 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002802A1 (en) * 1998-11-20 2000-05-24 Pfizer Products Inc. Dipeptide derivatives as growth hormone secretagogues
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
WO2004014415A1 (en) * 2002-08-09 2004-02-19 Societe De Conseil De Recherches Et D'applications Scientifiques, S.A.S. Growth hormone releasing peptides
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097173A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002802A1 (en) * 1998-11-20 2000-05-24 Pfizer Products Inc. Dipeptide derivatives as growth hormone secretagogues
WO2001092292A2 (en) * 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
WO2004014415A1 (en) * 2002-08-09 2004-02-19 Societe De Conseil De Recherches Et D'applications Scientifiques, S.A.S. Growth hormone releasing peptides
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
WO2005097174A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
WO2005097831A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Uses of isolated binding members capable of binding specifically to secretagogues
WO2005097173A2 (en) * 2004-04-07 2005-10-20 Gastrotech Pharma A/S Use of ghrelin for the treatment of hyperthyroidism

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARPINO PHILIP A: "Recent developments in ghrelin receptor (GHS-R1a) agonists and antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 12, no. 11, 2002, pages 1599 - 1618, XP002313948, ISSN: 1354-3776 *
DIXIT V D ET AL: "GHRELIN INHIBITS LEPTIN- AND ACTIVATION-INDUCED PROINFLAMMATORY CYTOKINE EXPRESSION BY HUMAN MONOCYTES AND T CELLS", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 114, no. 1, July 2004 (2004-07-01), pages 57 - 66, XP001207514, ISSN: 0021-9738 *
TOSHINAI K ET AL: "Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 281, no. 5, 16 March 2001 (2001-03-16), pages 1220 - 1225, XP002243977, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2006045314A2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP1426375A3 (en) Analgesic spiroindole derivatives
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
EP2330111A3 (en) Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
EP2175834B8 (en) Glp-1-fc fusion protein formulation
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2005070390A3 (en) Mitratapide oral solution
WO2006048450A3 (en) Peptides for use in the treating obesity
WO2005107384A3 (en) Methods for treating blood disorders with nitric oxide donor compounds
WO2003079991A3 (en) Method for administration of growth hormone via pulmonary delivery
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
WO2005097826A3 (en) Prokineticin 2beta peptide and its use
WO2008091704A3 (en) Treatment of cushing's syndrome and autism
WO2009071283A3 (en) Therapeutic use of desacyl ghrelin
WO2005086773A3 (en) A method for delivering therapeutic proteins to the intradermal compartment
WO2007144699A3 (en) Process for the preparation of alfuzosin
WO2005123777A3 (en) Method of treating granuloma annulare or sarcoid
WO2004058803A3 (en) Peptides that bind of the vegfr-2
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
EP1192943A3 (en) Use of growth hormone secretagogues in conjunction with physical exercise
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
WO2006092795A3 (en) Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05796742

Country of ref document: EP

Kind code of ref document: A2